Norgine

Aug 14, 2025

Norgine completes acquisition of Theravia

Jul 08, 2025

Swissmedic approves IFINWIL® (eflornithine) for children diagnosed with high-risk neuroblastoma (HRNB)

Apr 17, 2025

Norgine welcomes TGA registration in Australia of IFINWIL® (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]

Jan 24, 2025

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

Jan 06, 2025

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Oct 02, 2024

Norgine Announces Appointment of New CEO Janneke van der Kamp

Jun 16, 2020

Norgine B.V. Senior Management Changes: Christopher Bath Appointed Chief Operating Officer